[A25-01] Erdafitinib (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V
Last updated 01.04.2025
Project no.:
A25-01
Commission:
Commission awarded on 02.01.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with unresectable or metastatic urothelial carcinoma, harbouring susceptible fibroblast growth factor receptor 3 genetic alterations after prior therapy with a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting
- and for whom cisplatin-containing chemotherapy is suitable and who have not yet received such therapy; second-line treatment: added benefit not proven
- and for whom cisplatin-containing chemotherapy is unsuitable; second-line treatment: added benefit not proven
- and after prior platinum-containing chemotherapy, and for whom chemotherapy is suitable; third-line treatment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-01